Benjamin J. Zeskind

CEO Zeskind buys 2,400 shares of IMRX at $4.56; stock down 54.4% from 52-week high, reversing near-term decline ahead of 3-of-4 well-timed buys.

Benjamin J. Zeskind, President and CEO of Immuneering Corp, purchased 2,400 shares at $4.56, bringing his holdings to 2,315,252 shares post-transaction. The purchase occurs as IMRX trades at $4.60, down 54.4% from the 52-week high of $10.08 and off 14.7% in the 30-day window. The timing merits attention: across Zeskind's same-ticker history at IMRX, 3 of his 4 prior buys were well-timed at the 90-day mark, with two yielding returns of +98.1% and +99.8%, though his most recent buy (2025-07-02) is still underwater at -4.6% in the 30-day period. Against this backdrop, the company reported zero revenue in its latest quarter and a full-year net loss of $-13,460,895.00, with annual revenue declining 100.0% year-over-year. The combination of an insider with a demonstrated pattern of profitable entry timing at this specific ticker, paired with deteriorating fundamentals and acute near-term price pressure, presents a signal worth monitoring for what the CEO's conviction implies about near-term recovery prospects.

IMRX CEO Zeskind bought 10,000 shares across 2 transactions for $34,879.32 (blended $3.49); current price $3.45, 5-insider cluster.

Benjamin J. Zeskind, President and CEO, executed 2 separate purchases totaling 10,000 shares for $34,879.32 on consecutive days (2,985 shares at $3.38 on 2025-07-01 and 7,015 shares at $3.53 on 2025-07-02), raising his holdings from 2.30M to 2.31M shares. The company is currently unprofitable with $-15.0M net income, zero latest-quarter revenue, and -100.0% annual revenue growth, while the stock has risen 76.0% over the past 30 days and 144.7% over 90 days from a 52-week low of $1.03. Zeskind's cross-ticker track record shows 2 prior buys with an average 90-day return of -44.5%, and his prior IMRX buy on 2025-06-18 remains in early-stage accumulation. A 5-insider cluster buy pattern in the past 14 days suggests coordinated board or management interest, though the underlying company fundamentals remain severely distressed with deteriorating revenue and ongoing losses.

CEO Zeskind buys 21,000 IMRX shares at $2.39; stock -20.2% from 52-week high, company posted $-15.0M net loss with -100.0% revenue decline

Benjamin J. Zeskind, President and CEO, purchased 21,000 shares at $2.39 on 2025-06-18, adding to holdings of 2.30M shares. The purchase occurs while the stock trades -20.2% from its 52-week high, though the 30-day and 90-day price momentum have been +73.0% and +42.2% respectively. Fundamentally, the company faces serious headwinds: latest quarter revenue is $0.00, the company reported a net loss of $-15.0M, and annual revenue growth was -100.0%. This is paired with a concerning track record: Zeskind's single prior trade at IMRX (a buy on 2024-03-19) posted -44.5% over 90 days, and across all tickers his prior buys averaged -44.5% over 90 days with a 0% win rate. While a cluster of 4 other insiders also bought within the past 14 days, the combination of severe negative fundamentals, repeated underperformance of prior purchases, and zero profitability suggests this transaction warrants scrutiny given the weak operational backdrop.